» Articles » PMID: 16413612

Genetic Association Analysis of the Glutathione Peroxidase (GPX1) Gene Polymorphism (Pro197Leu) with Tardive Dyskinesia

Overview
Journal Psychiatry Res
Specialty Psychiatry
Date 2006 Jan 18
PMID 16413612
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

A possible involvement of oxidative stress in the pathophysiology of tardive dyskinesia (TD) has previously been proposed (reviewed in [Andreassen, O.A., Jorgensen, H.A., 2000. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Progress in Neurobiology 61, 525-541.]). Long-term administration of neuroleptics alters dopaminergic turnover, which results in increased formation of reactive oxygen species (ROS). This is hypothesized to lead to TD through neuronal toxicity as a consequence of oxidative stress. In the present study, the relationship between TD and a possible functional polymorphism of the human glutathione peroxidase (GPX1) gene (an important antioxidant enzyme) was studied in 68 chronic treatment-refractory patients with schizophrenia. A proline (Pro) to leucine (Leu) substitution at codon 197 (Pro197Leu) in the GPX1 gene was genotyped. No significant difference in total Abnormal Involuntary Movements Scale (AIMS) scores was observed among patients in the three genotype groups. Moreover, no significant differences in genotype or allele frequencies were observed between subjects with and without TD. Our results suggest that the GPX1 gene polymorphism does not confer increased susceptibility to TD, although further studies are warranted before a conclusion can be drawn.

Citing Articles

Correlation of Blood Biochemical Markers with Tardive Dyskinesia in Schizophrenic Patients.

Wu Q, Yuan F, Zhang S, Liu W, Miao Q, Zheng X Dis Markers. 2022; 2022:1767989.

PMID: 35299866 PMC: 8923804. DOI: 10.1155/2022/1767989.


Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Tsermpini E, Redensek S, Dolzan V Front Pharmacol. 2022; 12:834129.

PMID: 35140610 PMC: 8819690. DOI: 10.3389/fphar.2021.834129.


Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.

Shad M Behav Sci (Basel). 2021; 11(7).

PMID: 34209185 PMC: 8301006. DOI: 10.3390/bs11070097.


Effects of and Polymorphisms on the Risk of Schizophrenia in Chinese Han Population.

Liu C, Song S, Zhang J, Li X, Gao H Neuropsychiatr Dis Treat. 2020; 16:113-118.

PMID: 32021204 PMC: 6957098. DOI: 10.2147/NDT.S236298.


Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.

Chang F, Fung V Pharmgenomics Pers Med. 2014; 7:317-28.

PMID: 25378945 PMC: 4207069. DOI: 10.2147/PGPM.S52806.